tiprankstipranks
Ayala Pharmaceuticals Inc (AYLA)
NASDAQ:AYLA
US Market

Ayala Pharmaceuticals Stock Analysis & Ratings

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

AYLA FAQ

What was Ayala Pharmaceuticals’s price range in the past 12 months?
Ayala Pharmaceuticals lowest stock price was $0.70 and its highest was $14.95 in the past 12 months.
    What is Ayala Pharmaceuticals’s market cap?
    Currently, no data Available
    What is Ayala Pharmaceuticals’s price target?
    The average price target for Ayala Pharmaceuticals is $15.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $18.00 ,the lowest forecast is $12.00. The average price target represents 1011.11% Increase from the current price of $1.35.
      What do analysts say about Ayala Pharmaceuticals?
      Ayala Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Ayala Pharmaceuticals’s upcoming earnings report date?
        Ayala Pharmaceuticals’s upcoming earnings report date is Aug 18, 2022 which is in 6 days.
          How were Ayala Pharmaceuticals’s earnings last quarter?
          Ayala Pharmaceuticals released its earnings results on May 17, 2022. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.677 by $0.017.
            Is Ayala Pharmaceuticals overvalued?
            According to Wall Street analysts Ayala Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Ayala Pharmaceuticals pay dividends?
              Ayala Pharmaceuticals does not currently pay dividends.
              What is Ayala Pharmaceuticals’s EPS estimate?
              Ayala Pharmaceuticals’s EPS estimate is -$0.65.
                How many shares outstanding does Ayala Pharmaceuticals have?
                Ayala Pharmaceuticals has 14,085,283 shares outstanding.
                  What happened to Ayala Pharmaceuticals’s price movement after its last earnings report?
                  Ayala Pharmaceuticals reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.677. Following the earnings report the stock price went down -7.583%.
                    Which hedge fund is a major shareholder of Ayala Pharmaceuticals?
                    Among the largest hedge funds holding Ayala Pharmaceuticals’s share is ARK Investment Management LLC. It holds Ayala Pharmaceuticals’s shares valued at N/A.

                      ---

                      Ayala Pharmaceuticals Stock Analysis

                      Smart Score
                      N/A
                      Not Ranked
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $15.00
                      ▲(1011.11% Upside)
                      Moderate Buy
                      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Ayala Pharmaceuticals Inc

                      Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AbbVie
                      Amgen
                      Gilead Sciences
                      Moderna
                      Vertex Pharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis